
Sign up to save your podcasts
Or
In this week’s View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity.
Subscribe to Eagle’s Eye View
4.7
127127 ratings
In this week’s View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity.
Subscribe to Eagle’s Eye View
130 Listeners
326 Listeners
159 Listeners
866 Listeners
492 Listeners
32 Listeners
277 Listeners
87 Listeners
1,087 Listeners
60 Listeners
39 Listeners
186 Listeners
349 Listeners
424 Listeners
35 Listeners